It came hot on the heels of the group's acquisition of Ardea Biosciences, which has a gout treatment in late-stage development.
The Guardian(Jul 26, 2012)
In April, AstraZeneca agreed to buy Ardea BioSciences for $1.26 billion, giving it a new gout drug to swell its thin pipeline.
Reuters(Jun 30, 2012)
Biotech buy Pharmaceutical giant AstraZeneca of London will spend around US$1.26 billion to buy Ardea Biosciences, it announced on 23 April.
Nature(Apr 25, 2012)